Company Overview and News
RIMOUSKI, Quebec , May 23, 2018 (GLOBE NEWSWIRE) -- TELUS announced today that it will be enhancing its network service in the Lower North Shore. In partnership with the federal government’s Connect to Innovate program and the government of Quebec’s Société du Plan Nord, we will be building IP transport infrastructure and adding LTE cell towers in the Lower North Shore.
RIMOUSKI, Québec , 23 mai 2018 (GLOBE NEWSWIRE) -- TELUS annonce aujourd’hui qu’elle va bonifier la desserte de son réseau pour la région de la Basse-Côte-Nord. En partenariat avec le gouvernement fédéral (programme Brancher pour Innover) et le gouvernement du Québec (la Société du Plan Nord), nous allons créer une infrastructure de transport IP et déployer des tours cellulaires LTE en Basse-Côte-Nord.
The company's free cash flow is expected to grow significantly as it wraps up its fiber to the home project.
QUÉBEC, Québec, 16 mai 2018 (GLOBE NEWSWIRE) -- Le Comité d’investissement communautaire de TELUS à Québec célèbre aujourd’hui le dixième anniversaire d’un de ses événements annuels les plus importants, sa Célébration communautaire. À l’occasion de ce grand rassemblement qui vise à saluer le travail des organismes caritatifs qui contribuent à l’essor des communautés québécoises, François Gratton, vice-président à la direction, TELUS et Solutions partenaires et président, Solutions d’affaires Est du Canada et TELUS Québec, a annoncé le lancement de Mobilité pour l’avenir.
After an extremely busy week last week, there are only two Canadian Dividend All-Stars scheduled to report earnings this coming week. Unfortunately, neither are expected to increase dividends. However, we have plenty to catch up on from last week before banks start to report in two weeks.
VANCOUVER, Colombie-Britannique, 10 mai 2018 (GLOBE NEWSWIRE) -- TELUS Corporation (TELUS) (TSX:T) (NYSE:TU) a annoncé aujourd’hui que les candidats nommés dans la circulaire d’information du 7 mars 2018 ont été élus administrateurs de TELUS. Les résultats détaillés de l’élection des administrateurs ayant eu lieu à l’Assemblée générale annuelle le 10 mai 2018 (l’Assemblée) figurent ci-dessous.
VANCOUVER, British Columbia, May 10, 2018 (GLOBE NEWSWIRE) -- TELUS Corporation (TELUS) (TSX:T) (NYSE:TU) announced today that the nominees listed in the information circular dated March 7, 2018 were elected as directors of TELUS. The detailed results of the vote for the election of directors held at TELUS’ Annual General Meeting on May 10, 2018 (the Meeting) are set out below.
VANCOUVER, Colombie-Britannique, 10 mai 2018 (GLOBE NEWSWIRE) -- AVIS EST PAR LES PRÉSENTES DONNÉ que le conseil d’administration a déclaré un dividende trimestriel de 0,525 $ CA par action sur les actions ordinaires émises et en circulation. Ce dividende sera versé le 3 juillet 2018 aux détenteurs inscrits à la clôture des marchés le 8 juin 2018.
VANCOUVER, British Columbia, May 10, 2018 (GLOBE NEWSWIRE) -- NOTICE IS HEREBY GIVEN that the Board of Directors has declared a quarterly dividend of $0.525 Canadian per share on the issued and outstanding Common shares payable on July 3, 2018 to holders of record at the close of business on June 8, 2018.
MONTRÉAL, 01 mai 2018 (GLOBE NEWSWIRE) -- La 13e édition annuelle des Journées du bénévolat de TELUS débute aujourd’hui. Au cours des prochaines semaines, plus de 34 000 membres de l’équipe TELUS, actuels et retraités, ainsi que leurs proches et amis, participeront bénévolement à 2 000 activités pour aider à bâtir des communautés fortes, saines et durables partout au pays et dans le monde. Ces bénévoles seront ainsi appelés à nettoyer des berges, trier des denrées dans les banques alimentaires, lire des histoires aux jeunes, donner du sang, rénover des refuges ou encore planter des arbres.
VANCOUVER, British Columbia, May 01, 2018 (GLOBE NEWSWIRE) -- TELUS’ 13th annual TELUS Days of Giving kicks off today where more than 34,000 TELUS team members, retirees, family and friends will volunteer at 2,000 activities this year to help create healthier, stronger and more sustainable communities across Canada and around the world. Volunteer activities include shoreline cleanups, sorting food at food banks, reading to young students, donating blood, refurbishing shelters and planting trees.
Over the last five trading days, telecom stocks witnessed a roller-coaster ride as skepticism from fears of a murky trade war was replaced by euphoria surrounding a possible merger that could redefine the dynamics of the industry. The industry also witnessed one of the biggest IT projects ever undertaken in the country as commercial number portability services began in the Southeast with the remaining six regions joining the transition phase in the coming weeks.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 8, 2018) - (TSX:T)(NYSE:TU) TELUS Corporation - NOTICE IS HEREBY GIVEN that the Board of Directors has declared a quarterly dividend of $0.5050 Canadian per share on the issued and outstanding Common shares payable on April 2, 2018 to holders of record at the close of business on March 9, 2018.
Strong customer growth, including 156,000 postpaid wireless, Internet and TV customer additions, up 23 per cent over last year
The telecom industry had a stellar run on the bourse last week as most of the key stocks traded in the green. On the earnings front, U.S. telecom behemoth AT&T Inc. (T - Free Report) reported strong financial numbers in the fourth quarter of 2017 with both the top and the bottom line beating the Zacks Consensus Estimate. The company reported 4.1 million total wireless net adds, with 2.7 million in the U.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...